media article on viralytics, page-29

Seems you are interested in the business side.

Nobody will pick it up because the stock is in a lock down and the VC's pulling the strings in the background have a jack boot on its throat.

I am not speculating on the deal. If you study economic development of nations through technological innovation, take the entire biotech sector as a single corporate, then consider the macro factors of the pharma industry including PDLC's and patent expiries viz the size of the disease target markets, it is obvious a cornerstone deal with a large pharma is required for the benefit of all of Australia...and humanity.